Prophylactic and therapeutic topical povidone-iodine in coronavirus disease 2019 (COVID-19): What is the evidence?

Int Forum Allergy Rhinol. 2020 Dec;10(12):1271-1273. doi: 10.1002/alr.22735. Epub 2020 Nov 10.

Authors

Carol H Yan¹, Benjamin S Bleier²

Affiliations

¹ Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of California San Diego Health, San Diego, CA.
² Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA.

PMID: 33118690
DOI: 10.1002/alr.22735

No abstract available

Publication types

Editorial

MeSH terms

Aerosols
Anti-Infective Agents, Local / therapeutic use*
Antiviral Agents / therapeutic use*
COVID-19 / prevention & control*
COVID-19 / transmission
Centers for Disease Control and Prevention, U.S.
Evidence-Based Medicine
Humans
Particulate Matter
Povidone-Iodine / therapeutic use*
Respiratory Tract Infections / prevention & control*
Respiratory Tract Infections / transmission
SARS-CoV-2 / physiology*
United States
Viral Load
World Health Organization

Substances

Aerosols
Anti-Infective Agents, Local
Antiviral Agents
Particulate Matter
Povidone-Iodine